{"id":51742,"date":"2023-09-20T09:24:57","date_gmt":"2023-09-20T09:24:57","guid":{"rendered":"https:\/\/medsname.com\/eptus\/"},"modified":"2026-05-01T10:49:11","modified_gmt":"2026-05-01T10:49:11","slug":"eptus","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/eptus\/","title":{"rendered":"Eptus"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Eptus?<\/h3>\n<p style=\"margin:0;\"><strong>Eptus<\/strong> este un <strong>comprimat de eplerenon\u0103 25 \/ 50 mg<\/strong> de la Sun Pharma \u2014 un <strong>antagonist selectiv al receptorului mineralocorticoid<\/strong>. Eplerenona se deosebe\u0219te de spironolacton\u0103 prin <strong>selectivitatea mult mai mare pentru receptorul mineralocorticoid<\/strong> fa\u021b\u0103 de receptorii de progesteron \u0219i androgeni \u2014 evit\u00e2nd ginecomastia (5-10% la spironolacton\u0103) \u0219i menstrua\u021bia neregulat\u0103, \u00een schimbul unei poten\u021be moderat mai sc\u0103zute asupra receptorului mineralocorticoid \u0219i a unui pre\u021b mai ridicat. Utiliz\u0103ri de referin\u021b\u0103: <strong>disfunc\u021bia ventricular\u0103 st\u00e2ng\u0103 post-IM (EPHESUS 2003)<\/strong> \u2014 reducere a mortalit\u0103\u021bii din toate cauzele cu 15%; <strong>insuficien\u021b\u0103 cardiac\u0103 u\u0219oar\u0103 p\u00e2n\u0103 la moderat\u0103 cu frac\u021bie de ejec\u021bie redus\u0103 (EMPHASIS-HF 2011)<\/strong> \u2014 reducere cu 37% a deceselor cardiovasculare sau a spitaliz\u0103rilor pentru insuficien\u021b\u0103 cardiac\u0103; <strong>hiperaldosteronism primar<\/strong> \u0219i <strong>hipertensiune arterial\u0103 rezistent\u0103<\/strong>. Doz\u0103 tipic\u0103: 25-50 mg o dat\u0103 pe zi. Contraindicat \u00een hiperkaliemie &gt;5,5, eGFR &lt;30, boala Addison, inhibitori puternici concomitenti ai CYP3A4. Monitoriza\u021bi potasiul \u0219i creatinina la ini\u021biere, dup\u0103 1 s\u0103pt\u0103m\u00e2n\u0103, 1 lun\u0103, apoi la fiecare 3-4 luni.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n<h2 class=\"wp-block-heading\">Ce este Eptus?<\/h2>\n<p>Eptus sunt comprimate de eplerenon\u0103 25\/50 mg de la Sun Pharma, furnizate \u00een cutii de 30-90 de comprimate. Eplerenona a fost introdus\u0103 de Pfizer \u00een 2002 sub denumirea <strong>Inspra<\/strong> \u2014 primul antagonist selectiv al receptorului de mineralocorticoizi, dezvoltat special pentru a evita efectele secundare anti-androgene ale spironolactonei (ginecomastie, menstrua\u021bii neregulate, libido sc\u0103zut) prin eliminarea reac\u021biei \u00eencruci\u0219ate cu receptorii de progesteron \u0219i androgeni.<\/p>\n<h2 class=\"wp-block-heading\">Cum ac\u021bioneaz\u0103 eplerenona<\/h2>\n<p>Eplerenona antagonizeaz\u0103 selectiv <strong>receptorul de mineralocorticoizi (MR)<\/strong> din celulele principale ale tubului colector cortical. Efecte:<\/p>\n<ul>\n<li><strong>Reducerea reabsorb\u021biei de sodiu, reducerea excre\u021biei de potasiu<\/strong> \u2014 naturiez\u0103 u\u0219oar\u0103 cu re\u021binere de potasiu (efect de economisire a potasiului)<\/li>\n<li><strong>Efecte antifibrotice \u0219i anti-remodelare asupra miocardului<\/strong> \u2014 aldosterone induce fibroz\u0103 cardiac\u0103 independent de efectul s\u0103u de re\u021binere a s\u0103rurilor; blocarea receptorilor mineralocorticoizi (MR) reduce fibroza. Principalul mecanism al beneficiului mortalit\u0103\u021bii \u00een insuficien\u021b\u0103 cardiac\u0103 cu frac\u021bie de ejec\u021bie redus\u0103 (HF-REF).<\/li>\n<li><strong>F\u0103r\u0103 activitate anti-androgen\u0103 sau progestogen\u0103<\/strong> \u2014 principalul factor de diferen\u021biere fa\u021b\u0103 de spironolacton\u0103<\/li>\n<li><strong>Timp de \u00eenjum\u0103t\u0103\u021bire mai scurt dec\u00e2t spironolactona<\/strong> (4-6 ore vs 1,4 ore pentru substan\u021ba parental\u0103 + 16-24 ore pentru metaboli\u021bi)<\/li>\n<li><strong>Poten\u021b\u0103 mai mic\u0103 la receptorii mineralocorticoizi (MR) dec\u00e2t spironolactona<\/strong> \u2014 necesit\u0103 de obicei 25-50 mg pentru un efect echivalent cu 12,5-25 mg de spironolacton\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dovezi \u0219i utiliz\u0103ri<\/h2>\n<p><strong>STUDIUL EPHESUS (2003)<\/strong> \u2014 eplerenon\u0103 25-50 mg la 6.642 de pacien\u021bi cu disfunc\u021bie ventricular\u0103 st\u00e2ng\u0103 post-infart miocardic (FE \u226440%) + insuficien\u021b\u0103 cardiac\u0103 sau diabet. Reducere cu 15% a mortalit\u0103\u021bii din toate cauzele; reducere cu 17% a mortalit\u0103\u021bii cardiovasculare; reducere cu 21% a mortelor cardiace subite. A stabilit eplerenona ca terapie standard pentru disfunc\u021bia ventricular\u0103 st\u00e2ng\u0103 post-infart miocardic.<\/p>\n<p><strong>EMPHASIS-HF (2011)<\/strong> \u2014 eplerenon\u0103 25-50 mg la 2.737 de pacien\u021bi cu IC-REF NYHA II (FE \u226435%). Oprit\u0103 prematur datorit\u0103 beneficiului: reducere cu 37% a deceselor cardiovasculare sau a spitaliz\u0103rilor pentru insuficien\u021b\u0103 cardiac\u0103; reducere cu 24% a mortalit\u0103\u021bii din toate cauzele. A extins indica\u021biile pentru antagoni\u0219tii de receptor mineralocorticoid la IC-REF simptomatic\u0103 u\u0219oar\u0103 (RALES a studiat doar IC sever\u0103).<\/p>\n<p><strong>Alte utiliz\u0103ri:<\/strong><\/p>\n<ul>\n<li><strong>Hipertensiune rezistent\u0103<\/strong> \u2014 o alternativ\u0103 de linia a patra c\u00e2nd spironolactona este intolerabil\u0103 din cauza ginecomastiei<\/li>\n<li><strong>Hiperaldosteronism primar (sindromul Conn)<\/strong> \u2014 terapia medical\u0103 standard pentru hiperplazia adrenal\u0103 bilateral\u0103 c\u00e2nd spironolactona este slab tolerat\u0103<\/li>\n<li><strong>IC-REF<\/strong> \u2014 \u00een special post-IM sau IC simptomatic\u0103 u\u0219oar\u0103-moderat\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dozaj<\/h2>\n<p><strong>Disfunc\u021bie ventricular\u0103 st\u00e2ng\u0103 post-IM sau IC-REF:<\/strong> \u00eencepe\u021bi cu 25 mg o dat\u0103 pe zi; titra\u021bi la 50 mg o dat\u0103 pe zi la 4 s\u0103pt\u0103m\u00e2ni dac\u0103 potasiul este &lt;5,0 \u0219i este tolerat.<\/p>\n<p><strong>Hipertensiune rezistent\u0103 sau hiperaldosteronism primar:<\/strong> 25-50 mg o dat\u0103 pe zi; doze mai mari (p\u00e2n\u0103 la 100 mg) ocazional \u00een sindromul Conn sub \u00eengrijire specializat\u0103.<\/p>\n<p><strong>Administrare:<\/strong> cu sau f\u0103r\u0103 alimente, o dat\u0103 pe zi. Administrarea diminea\u021ba este de obicei cea mai u\u0219oar\u0103; nu este obligatorie.<\/p>\n<p><strong>Program de monitorizare:<\/strong><\/p>\n<ul>\n<li><strong>Valori ini\u021biale:<\/strong> potasiu (trebuie s\u0103 fie &lt;5,0 pentru \u00eenceput), creatinin\u0103, eGFR, TA, evaluarea simptomelor.<\/li>\n<li><strong>1 s\u0103pt\u0103m\u00e2n\u0103:<\/strong> repet\u0103 potasiul \u0219i creatinina.<\/li>\n<li><strong>1 lun\u0103 \u0219i 3 luni:<\/strong> potasiu, creatinin\u0103, TA.<\/li>\n<li><strong>Continuu:<\/strong> la fiecare 3-4 luni, sau mai devreme dac\u0103 func\u021bia renal\u0103 se modific\u0103 sau se ini\u021biaz\u0103 un medicament interactiv.<\/li>\n<li><strong>\u00centrerupe\u021bi sau reduce\u021bi:<\/strong> potasiu &gt;5,5, cre\u0219tere creatinin\u0103 &gt;30%, simptome de hiperkaliemie (sl\u0103biciune, palpita\u021bii), hipotensiune sever\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Eplerenon\u0103 vs Spironolacton\u0103<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:14px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Caracteristic\u0103<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Eplerenon\u0103<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Spironolacton\u0103<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">selectivitate RM<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Ridicat\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Sc\u0103zut\u0103 (de asemenea AR \u0219i PR)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Ginecomastie<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">&lt;1%<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">5-10% la 25-50 mg; p\u00e2n\u0103 la 50% la doze mari<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Neregularit\u0103\u021bi menstruale<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Rare<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Frecvente<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">poten\u021b\u0103 RM<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Doza mai mic\u0103 (25 mg \u2248 12,5 mg spironolacton\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Mai mare<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Timp de \u00eenjum\u0103t\u0103\u021bire<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">4-6 ore (o dat\u0103 pe zi este suficient\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">1,4 ore pentru substan\u021ba activ\u0103, 16-24 ore pentru metaboli\u021bi<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Risc de hiperkaliemie<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Similar<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Similar<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Baz\u0103 de dovezi (IC-FER)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">EPHESUS (post-IM), EMPHASIS-HF (IC u\u0219oar\u0103)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">RALES (IC sever\u0103)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Baz\u0103 de dovezi (HTA)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Studii mai mici; linia a 4-a<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">PATHWAY-2 (cel mai bun agent de linia a 4-a)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cost<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Mai mare<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Mai ieftin (off-patent)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Efecte Secundare<\/h2>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li><strong>Hiperkaliemie<\/strong> \u2014 limitare de doz\u0103; mai sever\u0103 \u00een BCR sau cu combina\u021bii ACEi\/ARB<\/li>\n<li>Ame\u021beli, hipotensiune ortostatic\u0103<\/li>\n<li>Oboseal\u0103<\/li>\n<li>Cre\u0219tere mic\u0103 a creatinei (a\u0219teptat\u0103; investiga\u021bi dac\u0103 &gt;30%)<\/li>\n<li>Disconfort gastrointestinal u\u0219or<\/li>\n<\/ul>\n<p><strong>Mai pu\u021bin frecvente:<\/strong><\/p>\n<ul>\n<li>Hiperkaliemie sever\u0103 cu aritmie cardiac\u0103<\/li>\n<li>Ginecomastie (rar\u0103 fa\u021b\u0103 de spironolacton\u0103)<\/li>\n<li>Angioedem (rar)<\/li>\n<li>Hiponatremie<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Contraindica\u021bii<\/h2>\n<ul>\n<li>Hiperkaliemie &gt;5,0 mmol\/L la baz\u0103 (pragul produc\u0103torului 5,0; unele ghiduri 5,5)<\/li>\n<li>Insuficien\u021b\u0103 renal\u0103 sever\u0103 (TFG &lt;30)<\/li>\n<li>Boala Addison<\/li>\n<li>Inhibitori puternici concuren\u021bi ai CYP3A4 (ketoconazol, itraconazol, claritromicin\u0103, ritonavir, nelfinavir, nefazodon\u0103)<\/li>\n<li>Diuretice economisitoare de potasiu sau suplimente de potasiu concurente (dec\u00e2t sub monitorizare specializat\u0103)<\/li>\n<li>Hipersensibilitate cunoscut\u0103<\/li>\n<\/ul>\n<p><strong>Sarcina:<\/strong> date limitate; spre deosebire de spironolacton\u0103, nu are mecanism anti-androgen, dar siguran\u021ba nu este stabilit\u0103 \u2014 utiliza\u021bi numai dac\u0103 beneficiul dep\u0103\u0219e\u0219te clar riscul. <strong>Al\u0103ptarea:<\/strong> date limitate; lua\u021bi \u00een considerare alternative.<\/p>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<ul>\n<li><strong>Inhibitori puternici ai CYP3A4 \u2014 CRITIC.<\/strong> Cre\u0219te nivelul de eplerenon\u0103 de 5-10 ori. Combina\u021bii contraindicate: ketoconazol, itraconazol, claritromicin\u0103, nefazodon\u0103, nelfinavir, ritonavir. Inhibitori moderati (eritromicin\u0103, fluconazol, diltiazem, verapamil) \u2014 lua\u021bi \u00een considerare reducerea dozei.<\/li>\n<li><strong>Inhibitori ACE, ARB, aliskiren<\/strong> \u2014 hiperkaliemie aditiv\u0103; monitoriza\u021bi potasiul s\u0103pt\u0103m\u00e2nal la ini\u021biere.<\/li>\n<li><strong>Diuretice economisitoare de potasiu, suplimente de potasiu<\/strong> \u2014 hiperkaliemie aditiv\u0103; evita\u021bi.<\/li>\n<li><strong>AINS<\/strong> \u2014 cre\u0219te riscul de AKI cu ACEi\/ARB + eplerenon\u0103 (efect cvadruplu).<\/li>\n<li><strong>Litiu<\/strong> \u2014 clearance redus; monitoriza\u021bi nivelurile.<\/li>\n<li><strong>Sunatoarea<\/strong> \u2014 induce CYP3A4; reduce nivelurile de eplerenon\u0103.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<p>P\u0103stra\u021bi Eptus la sub 25\u00b0C. Depozita\u021bi \u00een afara accesului copiilor.<\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">De ce s\u0103 alege\u021bi eplerenon\u0103 \u00een loc de spironolacton\u0103?<\/h3>\n<p>Dou\u0103 motive principale: (1) dac\u0103 spironolactona a cauzat ginecomastie, sensibilitate mamar\u0103 sau iregularit\u0103\u021bi menstruale \u2014 selectivitatea MR a eplerenonei evit\u0103 acestea. (2) Disfunc\u021bie ventricular\u0103 st\u00e2ng\u0103 post-IM \u2014 EPHESUS a validat specific eplerenona \u00een aceast\u0103 popula\u021bie; RALES pentru spironolacton\u0103 a studiat doar IC sever\u0103. Spironolactona r\u0103m\u00e2ne mai ieftin\u0103 \u0219i mai potent\u0103 pe mg; avantajele eplerenonei sunt \u00een principal tolerabilitatea \u0219i dovezile specifice post-IM.<\/p>\n<h3 class=\"wp-block-heading\">Eptus va cre\u0219te nivelul meu de potasiu?<\/h3>\n<p>Da \u2014 eplerenone este economisitor de potasiu. Hiperkalemia &gt;5,5 este toxicitatea limitatoare de doz\u0103, cel mai frecvent \u00een BCR sau \u00een combina\u021bie cu ACEi\/ARB. Verifica\u021bi la evaluarea ini\u021bial\u0103 (trebuie s\u0103 fie &lt;5,0), dup\u0103 1 s\u0103pt\u0103m\u00e2n\u0103, 1 lun\u0103 \u0219i apoi la fiecare 3-4 luni. Ad\u0103uga\u021bi sau ajusta\u021bi terapia dac\u0103 potasiul dep\u0103\u0219e\u0219te 5,5.<\/p>\n<h3 class=\"wp-block-heading\">Pot lua ibuprofen cu Eptus?<\/h3>\n<p>Tratamentele scurte sunt de obicei acceptabile cu monitorizarea potasiului. AINE-uri cronice + ACEi\/ARB + eplerenon cresc substan\u021bial riscul de IRA (dublu efect negativ). Prefera\u021bi paracetamol.<\/p>\n<h3 class=\"wp-block-heading\">Ce alimente ar trebui s\u0103 evit?<\/h3>\n<p>Substitutele de sare cu con\u021binut sc\u0103zut de sodiu (care folosesc adesea clorur\u0103 de potasiu) \u0219i alimentele bogate \u00een potasiu \u00een cantit\u0103\u021bi mari (banane, portocale, ap\u0103 de nuc\u0103 de cocos) \u2014 toate cresc nivelul de potasiu. Por\u021bii normale sunt acceptabile; evita\u021bi dietele \u00eenc\u0103rcate inten\u021bionat cu potasiu.<\/p>\n<h3 class=\"wp-block-heading\">Unde pot cump\u0103ra Eptus online?<\/h3>\n<p>Pute\u021bi cump\u0103ra Eptus (eplerenon 25\/50 mg, 30-90 comprimate) de la MedsBase cu ambalaj discret \u0219i livrare la nivel mondial.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 class=\"wp-block-heading\">Medicamente conexe pentru cardiologie \u0219i hipertensiune<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/atorvatin\/\">Atorvatin \u2014 Atorvastatin 5 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/ecosprin\/\">Ecosprin \u2014 Aspirin\u0103 75\/150 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lasix-injection\/\">Lasix Injectabil \u2014 Furosemid\u0103 40 mg\/4 mL fiole IV<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lipvas\/\">Lipvas \u2014 Atorvastatin\u0103 10\/20\/40 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/rosuline\/\">Rosulin\u0103 \u2014 Rosuvastatin\u0103 5\/10 mg<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tenoric\/\">Tenoric \u2014 Combina\u021bie de Atenolol + Clortalidon\u0103<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/high-blood-pressure-medication\/\"><strong>R\u0103sfoi\u021bi toate medicamentele pentru hipertensiune arterial\u0103<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Dezaprobare medical\u0103.<\/strong> Aceast\u0103 pagin\u0103 are scop informativ \u0219i nu \u00eenlocuie\u0219te sfatul medical al unui medic calificat. Hipertensiunea, insuficien\u021ba cardiac\u0103 \u0219i aritmiile necesit\u0103 diagnostic, monitorizare \u0219i individualizarea dozei de c\u0103tre un medic \u2014 utiliza\u021bi \u00eentotdeauna beta-blocante sub \u00eendrumare medical\u0103.<\/div>","protected":false},"excerpt":{"rendered":"<p>Eptus este comprimatul de eplerenon\u0103 25\/50 mg al Sun Pharma \u2014 antagonist selectiv al receptorului mineralocorticoid. Dezvoltat de Pfizer ca Inspra (2002) special pentru a evita efectele secundare anti-androgene ale spironolactonei (ginecomastie 5-10%, menstrua\u021bie neregulat\u0103). EPHESUS (2003) a validat utilizarea \u00een disfunc\u021bia ventricular\u0103 st\u00e2ng\u0103 post-IM \u2014 reducere a mortalit\u0103\u021bii cu 15%. EMPHASIS-HF (2011) a extins utilizarea la insuficien\u021b\u0103 cardiac\u0103 u\u0219oar\u0103 cu frac\u021bie de ejec\u021bie redus\u0103 \u2014 reducere cu 37% a deceselor cardiovasculare\/spitaliz\u0103rilor. De asemenea, pentru HTA rezistent\u0103, sindromul Conn. Monitoriza\u021bi \u00eendeaproape potasiul \u0219i creatinina.<\/p>","protected":false},"featured_media":51743,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[3403,3404],"class_list":{"0":"post-51742","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-heart-blood-pressure","9":"product_cat-high-blood-pressure-medication","10":"product_tag-eplerenone","11":"product_tag-eptus","13":"first","14":"outofstock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/51742","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=51742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/51743"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=51742"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=51742"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=51742"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=51742"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}